- Home
- ICON vs XRTX Comparison
ICON vs XRTX Comparison
Compare ICON & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICON
- XRTX
- Stock Information
- Founded
- ICON 2023
- XRTX 2011
- Country
- ICON Greece
- XRTX Canada
- Employees
- ICON N/A
- XRTX N/A
- Industry
- ICON
- XRTX Pharmaceuticals and Biotechnology
- Sector
- ICON
- XRTX Health Care
- Exchange
- ICON Nasdaq
- XRTX Nasdaq
- Market Cap
- ICON 4.7M
- XRTX 4.2M
- IPO Year
- ICON 2024
- XRTX N/A
- Fundamental
- Price
- ICON $2.11
- XRTX $0.83
- Analyst Decision
- ICON Strong Buy
- XRTX
- Analyst Count
- ICON 1
- XRTX 0
- Target Price
- ICON $4.50
- XRTX N/A
- AVG Volume (30 Days)
- ICON 33.9K
- XRTX 48.2K
- Earning Date
- ICON 09-10-2025
- XRTX 11-14-2025
- Dividend Yield
- ICON 100.00%
- XRTX N/A
- EPS Growth
- ICON N/A
- XRTX N/A
- EPS
- ICON N/A
- XRTX N/A
- Revenue
- ICON $6,137,000.00
- XRTX N/A
- Revenue This Year
- ICON $94.05
- XRTX N/A
- Revenue Next Year
- ICON $18.81
- XRTX N/A
- P/E Ratio
- ICON N/A
- XRTX N/A
- Revenue Growth
- ICON 25.60
- XRTX N/A
- 52 Week Low
- ICON $1.60
- XRTX $0.66
- 52 Week High
- ICON $130.80
- XRTX $2.51
- Technical
- Relative Strength Index (RSI)
- ICON 46.72
- XRTX 50.73
- Support Level
- ICON $1.87
- XRTX $0.80
- Resistance Level
- ICON $2.18
- XRTX $0.86
- Average True Range (ATR)
- ICON 0.11
- XRTX 0.04
- MACD
- ICON 0.02
- XRTX 0.00
- Stochastic Oscillator
- ICON 57.83
- XRTX 50.25
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.